Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD20 CAR-CD28-4-1BB-CD3zeta T lymphocytes MB-106

A preparation of autologous T lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) cluster of differentiation 20 (CD20) and coupled to the co-stimulatory signaling domain CD28, the signaling domain of 4-1BB (CD137), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3zeta), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD20CAR-CD28-4-1BB-CD3zeta T lymphocytes MB-106 specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated B-cell specific surface phosphoprotein that plays a role in the differentiation of B cells into plasma cells, is overexpressed in B-cell lineage malignancies and certain melanoma cell subpopulations.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CD20 CAR-T cells MB-106
autologous anti-CD20CAR-CD28-4-1BB-CD3zeta-expressing T lymphocytes MB-106
CD20-targeted autologous CAR-T cells MB-106
Code name:MB 106
MB-106
MB106
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search